𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A peptide–doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo

✍ Scribed by Jones, Raymond E.; DeFeo-Jones, Deborah; Garsky, Victor M.; Wong, Bradley K.; Feng, Dong-Mei; Bolyar, Trina; Haskell, Kathleen; Kiefer, David M.; Leander, Karen; McAvoy, Elizabeth; Lumma, Patricia; Wai, Jenny; Senderak, Edith T.; Motzel, Sherri L.; Keenan, Kevin; Zwieten, Matthew Van; Lin, Jiunn H.; Freidinger, Roger; Huff, Joel; Oliff, Allen

Book ID
109829380
Publisher
Nature Publishing Group
Year
2000
Tongue
English
Weight
109 KB
Volume
6
Category
Article
ISSN
1078-8956

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Synthesis and biological evaluation of a
Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP)
✍ Ralph Graeser; Da-Eun Chung; Norbert Esser; Sandra Moor; Christoph Schächtele; C 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 518 KB

## Abstract The prostate‐specific antigen (PSA) is a serine protease that is over‐expressed in prostate carcinoma and represents a molecular target for selectively releasing an anticancer agent from a prodrug formulation. We have recently investigated a macromolecular prodrug strategy for improved